Brand Name(s): Relafen
CAS nº: 42924-53-8
(na byoo’ me tone)
About nabumetone
This new site is dedicated exclusively to nabumetone.
It provides you with the most extensive product information and up-to-date resources regarding this medication, including related news articles, medical studies, an image library and all the necessary information on dosage and side effects.
Whether you are an average consumer or pharma industry professional, you can now find out everything you need to know about nabumetone, as well as take part in our open discussion forum by sharing your own knowledge and experiences with people who are using this medication.
This unique site will also provide you with inside industry news on which companies or organizations are playing an important part in its research, development, production and promotion. It is your one-stop site for a total nabumetone experience!
Why is this medication prescribed?
Nabumetone is in a group of drugs called nonsteroidal anti-inflammatory drugs (NSAIDs), which are drugs with analgesic, antipyretic and anti-inflammatory effects - they reduce pain, fever and inflammation. Nabumetone works by reducing hormones that cause swelling and pain in the body.
This medication is used to treat the symptoms of osteoarthritis and rheumatoid arthritis.
Latest News
Arthritis Drug Settlement
We have a Your Stories Q&A about the arthritis drug Relafen, and its generic counterpart...
[more]Some NSAIDS Safe in Ulcerative Colitis or Crohn's
Rochester, Minn., - Patients with inflammatory bowel disease can use once-forbidden non-steroidal...
[more]BPC 2005 Prize winners
Two PhD students, working within the Pharmaceutical Science Research Division were awarded prizes...
[more]Bad News for Cox-2 Inhibitors Was Good News for Mobic
Washington -The departure of Vioxx (rofecoxib) from pharmacists' shelves last September triggered a...
[more]Eon Labs - Generic News - initial public stock offering - Brief Article - Statistical Data Included
Generic drug maker Eon Labs priced its initial public stock offering of 9.8 million shares at $15...
[more]